Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efpeglenatide

AMPLITUDE-D

Sanofi · Phase 3 · Terminated · Enrollment 908

NCT03684642

EudraCT 2017-002956-10

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Efpeglenatide 4 mgn/rn/rn/rn/r
Efpeglenatide 6 mgn/rn/rn/rn/r
Dulaglutide 1.5 mgn/rn/rn/rn/r

Not shown

  • Efpeglenatide 4 mg: endpoint not reported
  • Efpeglenatide 6 mg: endpoint not reported
  • Dulaglutide 1.5 mg: endpoint not reported